BRIEF published on 04/17/2026 at 09:43, 6 months 19 days ago Heidelberg Pharma annonce un changement au sein de son conseil d'administration. Biotechnologie Essai Clinique Nomination Du Directeur Financier Heidelberg Pharma Changement Exécutif
BRIEF published on 04/17/2026 at 09:43, 6 months 19 days ago Heidelberg Pharma Announces Executive Board Change CFO Appointment Biotech Clinical Trial Heidelberg Pharma Executive Change
PRESS RELEASE published on 04/17/2026 at 09:38, 6 months 19 days ago Heidelberg Pharma Announces Change in Executive Board Heidelberg Pharma announces change in Executive Board as CFO Walter Miller departs end of April, Peter Willinger appointed as new CFO from 1 May 2026. Company specializes in developing Antibody Drug Conjugates (ADCs) CFO Executive Board Heidelberg Pharma Antibody Drug Conjugates ADCs
BRIEF published on 04/09/2026 at 14:31, 6 months 27 days ago Heidelberg Pharma fait progresser son candidat ADC HDP-101 vers la phase II des essais cliniques. Heidelberg Pharma Essai De Phase II Recherche Clinique Myélome Multiple ADC HDP-101
BRIEF published on 04/09/2026 at 14:31, 6 months 27 days ago Heidelberg Pharma Advances ADC Candidate HDP-101 to Phase II Trial Clinical Research Heidelberg Pharma Phase II Trial Multiple Myeloma ADC HDP-101
PRESS RELEASE published on 04/09/2026 at 14:26, 6 months 27 days ago EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101 Heidelberg Pharma AG determines recommended Phase II dose for ADC candidate HDP-101 in multiple myeloma trial, plans Phase IIa initiation shortly Heidelberg Pharma AG Multiple Myeloma ADC Candidate Phase II Dose Phase IIa Trial
BRIEF published on 04/04/2026 at 10:12, 7 months 2 days ago Heidelberg Pharma to Showcase ADC Technology at AACR 2026 Heidelberg Pharma ADC Technology Prostate Cancer AACR 2026 HDP-103
BRIEF published on 04/04/2026 at 10:12, 7 months 2 days ago Heidelberg Pharma présentera sa technologie ADC lors du congrès AACR 2026 Heidelberg Pharma Cancer De La Prostate Technologie ADC AACR 2026 HDP-103
PRESS RELEASE published on 04/04/2026 at 10:07, 7 months 2 days ago Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026 Heidelberg Pharma to present promising preclinical data of Amanitin-based ADC HDP-103 targeting mCRPC at AACR Annual Meeting 2026 in San Diego Heidelberg Pharma Amanitin-based ADC ADC Technology Platform AACR Annual Meeting 2026 MCRPC
BRIEF published on 03/26/2026 at 07:12, 7 months 11 days ago Heidelberg Pharma publie ses résultats financiers pour 2025 et ses perspectives pour 2026. Résultats Financiers Heidelberg Pharma Mesures De Réduction Des Coûts Technologie ADC Perspectives 2026
Published on 11/06/2026 at 13:00, 1 hour 42 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 hours 12 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 hours 12 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 9 hours 27 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 14:36, 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 11/06/2026 at 09:07, 5 hours 35 minutes ago Mise à disposition de la note d'information de M14 dans le cadre de l'OPR visant les actions BOURRELIER GROUP
Published on 11/06/2026 at 09:04, 5 hours 37 minutes ago Mise à disposition de la note d'information en réponse établie par BOURRELIER GROUP initiée par M14
Published on 11/05/2026 at 18:21, 20 hours 20 minutes ago Capital et droits de vote au 31 octobre 2026
